Evidence map›Paper›PMID 30940480›Full record

ArticleUrology2019

Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.

Mina M Fam, Jonathan G Yabes, Liam C Macleod, Jathin Bandari, Robert M Turner, Samia H Lopa, Alessandro Furlan, Christopher P Filson, Benjamin J Davies, Bruce L Jacobs

Abstract read
In one paragraph

Article in Urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choice.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Mina M FamDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Jonathan G YabesDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA.
Liam C MacleodDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: macleodl2@upmc.edu.
Jathin BandariDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Robert M TurnerDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Samia H LopaDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA.
Alessandro FurlanDepartment of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Christopher P FilsonDepartment of Urology, Emory University, Atlanta, GA.
Benjamin J DaviesDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Bruce L JacobsDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
NCI NIH HHS P30 CA047904
6 · The paper itself

Abstract

objectiveTo characterize the use of multiparametric magnetic resonance imaging (mpMRI) in male Medicare beneficiaries electing active surveillance for prostate cancer. mpMRI has emerged as a tool that may improve risk-stratification and decrease repeated biopsies in men electing active surveillance. However, the extent to which mpMRI has been implemented in active surveillance has not been established.

methodsUsing Surveillance, Epidemiology, and End Results registry data linked to Medicare claims data, we identified men with localized prostate cancer diagnosed between 2008 and 2013 and managed with active surveillance. We classified men into 2 treatment groups: active surveillance without mpMRI and active surveillance with mpMRI. We then fit a multivariable logistic regression models to examine changing mpMRI utilization over time, and factors associated with the receipt of mpMRI.

resultsWe identified 9467 men on active surveillance. Of these, 8178 (86%) did not receive mpMRI and 1289 (14%) received mpMRI. The likelihood of receiving mpMRI over the entire study period increased by 3.7% (P = .004). On multivariable logistic regression, patients who were younger, white, had lower comorbidity burden, lived in the northeast and west, had higher incomes and lived in more urban areas had greater odds of receiving mpMRI (all P < .05).

conclusionFrom 2008 to 2013, use of mpMRI in active surveillance increased gradually but significantly. Receipt of mpMRI among men on surveillance for prostate cancer varied significantly across demographic, geographic, and socioeconomic strata. Going forward, studies should investigate causes for this variation and define ideal strategies for equitable, cost-effective dissemination of mpMRI technology.

Indexed as

Watchful WaitingAgedAged, 80 and overHumansMaleMedicareMultiparametric Magnetic Resonance ImagingProcedures and Techniques UtilizationProstatic NeoplasmsUnited States

Identifiers

PMID30940480
PMCPMC6660379

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.